What’s Been Recently Published About Hep C (December/January)

What's Been Recently Published About Hep CThe following highlights a variety of December/January published studies, articles, and press releases about hepatitis C and hepatitis C treatments.

Alimentry Pharmacology & Therapeutis (January 2017)

Summary: This study looked at the effectiveness and predictors of taking pegylated interferon with ribavirin (PR) and patients taking sofosbuvir (SOF) and PR. SVR ranged from 80.9% in the PR group to 96.1% in PR+SOF treated patients. Treatment-experienced patients with cirrhosis showed a suboptimal SVR of 68% for SOF+RBV but a high SVR of 90–95% for Daklinza+SOF±RBV. The safety analysis showed more adverse events and a stronger decline of haemoglobin for RBV based regimens.

Summary: This study looked at the effectiveness and predictors of taking sofosbuvir and ribavirin for 6 months versus taking the treatment sofosbuvir with pegylated interferon with ribavirin for 3 months. Group one achieved a 94% cure rate. In group two 78.7% achieved SVR. These results were similar to those achieved in other clinical trials.

Hepatology (December 2016)

Summary: Combining different DAAs with a variety of mechanisms may help shorten required treatment durations. This study aimed to find the treatment combination promising the best results the fastest. The study gave patients elbasvir/grazoprevir and sofosbuvir for 4-12 weeks. Patients being retreated were given the compound with ribavirin for 12 weeks. Cure rates were as follows:

Patients Treatment Weeks SVR
Without liver cirrhosis hep C genotype 1 4 32%
6 87%
With liver cirrhosis hep C genotype 1 4 80%
6 81%
Without liver cirrhosis hep C genotype 3 6 93%
8 100%
With liver cirrhosis hep C genotype 3 12 83%

The Lancet (December 2016/January 2017)

Summary: This clinical trial looked at the safety and effectiveness of RG-101, a hepatocyte targeted N-acetylgalactosamine conjugated anti-miR-122 oligonucleotide. The trial showed that RG-101 could achieve SVR after 4 weeks of treatment.

Recent Press Releases by Pharmaceutical Companies

Patients Treatment Weeks Treatment SVR
GT1 without cirrhosis, some with the resistance-associated Y93H virus variant 8 Glecaprevir / Pibrentasvir 99%
12

Technivie

100%